Efficacy of HDAC inhibitors was well established in hematologic malignancies, but most clinical trials failed to demonstrate clinical benefit as a single agent in solid cancers, including pancreatic cancer [53]. This evidence concerns the gene HDAC9 and familial pancreatic carcinoma.